secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEXX LABORATORIES INC /DE (IDXX)
CIK:        0000874716
Form:       8-K
Filed at:   2022-11-01T23:59:59+00:00
Accession:  0000950123-22-010618
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEXX Q3 revenue $842M (+8% organic); EPS $2.15 (+13% comparable); updates FY2022 guidance
--------------------------------------------------------------------------------

- Q3 revenue $842M, +4% reported, +8% organic; CAG Diagnostics recurring revenue +5% reported, +9% organic.
- EPS $2.15, +6% reported, +13% comparable; operating margin 29.1%, +100 bps comparable.
- Record global premium instrument placements, +10% YoY; installed base +14%.
- FY2022 guidance: revenue growth 3.5-4.5% reported, 6.5-7.5% organic; EPS $7.74-$7.98.
- Foreign currency headwinds: ~4% revenue impact, ~$0.25 EPS impact for FY2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874716/000095012322010618/0000950123-22-010618-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874716/000095012322010618/idxx-8k_20221101.htm
  HTML page:      https://secwatch.observer/filing/0000950123-22-010618

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer